Reversal of pathology in CHMP 2B-mediated frontotemporal dementia patient cells using RNA interference

Journal of Gene Medicine

Volumn 14, Issue 8, 2012, Pages 521-529

  Nielsen, Troels Tolstrup ^a,b   Mizielinska, Sarah ^c   Hasholt, Lis ^b   Isaacs, Adrian M ^c   Nielsen, Jørgen E ^a,b   Johannsen, Peter ^a   Dementia, Danish ^a   Gade, Anders ^d   Gydesen, Susanne ^e   Thusgaard, Tove ^f   Holm, Ida ^g   Englund, Elisabet ^h   Brown, Jeremy ⁱ   Fisher, Elizabeth ^c   Rossor, Martin ^c   Collinge, John ^c  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Psychiatry Region Zealand   (Denmark)

^f Randers Hospital ^*

^g RANDERS REGIONAL HOSPITAL   (Denmark)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

CHMP2B; Frontotemporal dementia; FTD 3; Lentiviral vectors; RNAi

Indexed keywords

LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; CD63 ANTIGEN; CD63 PROTEIN, HUMAN; CHMP2B PROTEIN, HUMAN; ESCRT PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CHMP2B GENE; CONTROLLED STUDY; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; ANALYSIS OF VARIANCE; CELL CULTURE; ENDOSOME; FIBROBLAST; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; LENTIVIRINAE; METABOLISM; PATHOLOGY; PHENOTYPE;

ANALYSIS OF VARIANCE; ANTIGENS, CD63; CELLS, CULTURED; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; ENDOSOMES; FIBROBLASTS; FRONTOTEMPORAL DEMENTIA; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; PHENOTYPE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84865432155     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2649     Document Type: Article

References (40)

1. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 2003; 74: 1206-1209.
2. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002; 58: 1615-1621.
3. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
4. McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001; 58: 1803-1809.
5. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011; 82: 476-486.
6. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256.
7. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268.
8. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005; 37: 806-808.
9. van der Zee J, Urwin H, Engelborghs S, et al. CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet 2008; 17: 313-322.
10. Urwin H, Ghazi-Noori S, Collinge J, Isaacs A. The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans 2009; 37: 208-212.
11. Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 2002; 3: 893-905.
12. Stuchell-Brereton MD, Skalicky JJ, Kieffer C, et al. ESCRT-III recognition by VPS4 ATPases. Nature 2007; 449: 740-744.
13. Obita T, Saksena S, Ghazi-Tabatabai S, et al. Structural basis for selective recognition of ESCRT-III by the AAA ATPase Vps4. Nature 2007; 449: 735-739.
14. Urwin H, Authier A, Nielsen JE, et al. Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Hum Mol Genet 2010; 19: 2228-2238.
15. Metcalf D, Isaacs AM. The role of ESCRT proteins in fusion events involving lysosomes, endosomes and autophagosomes. Biochem Soc Trans 2010; 38: 1469-1473.
16. Ghazi-Noori S, Froud KE, Mizielinska S, et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain 2012; 135: 819-832.
17. Open Biosystems. Vector product information. https://www.openbiosystems.com/ProductLiterature.aspx?AliasPath=/RNAi/shRNAmirLibraries/GIPZLentiviralshRNAmir&CatalogNumber=RHS4346 [17 July 2012].
18. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
19. Nielsen TT, Jakobsson J, Rosenqvist N, Lundberg C. Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants. BMC Biotechnol 2009; 9: 13.
20. Nielsen TT, Marion I, Hasholt L, Lundberg C. Neuron-specific RNA interference using lentiviral vectors. J Gene Med 2009; 11: 559-569.
21. Horvath L, van Marion I, Tai K, Nielsen TT, Lundberg C. Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. J Gene Med 2011; 13: 188-197.
22. Donadini A, Giodini A, Sanvito F, Marchisio PC, Biffo S. The human ITGB4BP gene is constitutively expressed in vitro, but highly modulated in vivo. Gene 2001; 266: 35-43.
23. Nathanson JL, Yanagawa Y, Obata K, Callaway EM. Preferential labelling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. Neuroscience 2009; 161: 441-450.
24. Mahairaki V, Xu L, Farah MH, et al. Targeted knock-down of neuronal nitric oxide synthase expression in basal forebrain with RNA interference. J Neurosci Methods 2009; 179: 292-299.
25. Xu S, Liu M, Zhang T, et al. Effect of lentiviral shRNA of Nogo receptor on rat cortex neuron axon outgrowth. Can J Neurol Sci 2011; 38: 133-138.
26. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-1010.
27. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008; 105: 5868-5873.
28. Rohrer JD, Ahsan RL, Isaacs AM, et al. Presymptomatic generalized brain atrophy in frontotemporal dementia caused by CHMP2B mutation. Dement Geriatr Cogn Disord 2009; 27: 182-186.
29. Boudreau RL, Rodriguez-Lebron E, Davidson BL. RNAi medicine for the brain: progresses and challenges. Hum Mol Genet 2011; 20: R21-R27.
30. Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy for the nervous system. Hum Mol Genet 2011; 20: R28-R41.
31. Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 2009; 17: 1053-1063.
32. Pfister EL, Kennington L, Straubhaar J, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009; 19: 774-778.
33. Warby SC, Montpetit A, Hayden AR, et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009; 84: 351-366.
34. Drouet V, Perrin V, Hassig R, et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 2009; 65: 276-285.
35. Alves S, Nascimento-Ferreira I, Auregan G, et al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008; 3: e3341.
36. Carroll JB, Warby SC, Southwell AL, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 2011; 19: 2178-2185.
37. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003; 100: 7195-7200.
38. Belly A, Bodon G, Blot B, et al. CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines. J Cell Sci 2010; 123: 2943-2954.
39. Lee JA, Beigneux A, Ahmad ST, Young SG, Gao FB. ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol 2007; 17: 1561-1567.
40. Morita E, Sandrin V, McCullough J, et al. ESCRT-III protein requirements for HIV-1 budding. Cell Host Microbe 2011; 9: 235-242.